关于报告
肿瘤学护理的改善是由生物标志物测试的不断增长和使用的驱动。通过通知护理团队，这种测试会影响健康结果，必威手机APP特定的靶向疗法是否可能对特定患者有效。然而，在常规护理中，生物标志物测试水平在肿瘤类型和生物标志物之间差异很大，并且遵守测试指南的依从性不同。该报告讨论了限制美国实体瘤生物标志物测试的主要障碍，以及它们在不断变化的医疗保健领域中如何发展。必威手机APP它进一步提供解决方案，以帮助减少肿瘤学中的这些测试障碍，并确保完全实现治疗益处。
报告摘要
An increased understanding of genetic and other molecular alterations in solid tumors — along with the development of targeted biomarker-based treatments for cancers with such alterations — have led to major improvements in patient care, overall survival, and quality of life outcomes. As such, biomarker testing has emerged as an important part of cancer care. However, there are several barriers to oncology biomarker testing for solid tumors including suboptimal tissue procurement and triaging; challenges with continuity of care across institutions; fragmented insurance coverage and inadequate reimbursement of testing; fragmented testing guidelines; and low awareness of actionable biomarkers by stakeholders. These result in operational inefficiencies in biomarker testing, limit awareness of available tests, and disincentivize broad and optimal use of testing. Collaboration across multiple stakeholders will be required to bring about a future with better patient outcomes through more robust diagnostic testing in cancer, and this report profiles potential solutions to help reduce testing barriers.
